HK Stock Market Move | PEGBIO CO-B(02565) rose by more than 5% and the listing application for PB-119 has been approved. The company is accelerating its global commercialization strategy.

date
13:39 18/11/2025
avatar
GMT Eight
PAG Biopharma-B (02565) rose over 5%, as of the time of publication, it increased by 5.11% to HK$63.8, with a trading volume of HK$29.2559 million.
PEGBIO CO-B(02565) rose more than 5%, as of press time, it increased by 5.11% to 63.8 Hong Kong dollars, with a turnover of 29.2559 million Hong Kong dollars. On the news front, PegBio Pharmaceuticals recently announced that the China National Medical Products Administration has approved the new drug application for the company's core product PB-119. Pedacan (PB-119) is a new generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by the company, administered once a week. This product has been classified as a national original Class 1 new drug recognized by the national major scientific and technological special project for "significant new drug creation". It is worth mentioning that in October of this year, PegBio Pharmaceuticals announced a strategic partnership with PDC FZ-LLC, a leading medical research and development institution in the United Arab Emirates, exclusively granting it the development, distribution, marketing, and commercialization rights for PegBio's core product Visepegenatide (PB-119) in the Middle East and Africa. This collaboration marks a key step in PegBio Pharmaceuticals' global commercialization strategy.